Greg Zante - Sep 28, 2021 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Financial Officer
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Sep 28, 2021
Transactions value $
-$14,989
Form type
4
Date filed
9/30/2021, 05:43 PM
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +6.67K +7.4% $0.00 96.8K Sep 28, 2021 Direct F1, F2
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$15K -2.31K -2.38% $6.50 94.5K Sep 28, 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2020, 33.33% of which vested on September 28, 2021 upon the achievement of a non-financial performance goal.
F2 Includes 373 shares acquired on May 20, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to a performance restricted stock unit award.